Showing results (501-510 of 511) with videos related to
Sort By:
Pageof 52
Immunity|March 10, 2021
Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discoveryShin-Heng Chiou, Diane Tseng, Alexandre Reuben, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2024
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLCAmin H Nassar, Ritujith Jayakrishnan, Jamie Feng, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2025
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort ABenjamin Besse, Koichi Goto, Yongsheng Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2017
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET RegistryOliver Gautschi, Julie Milia, Thomas Filleron, et al.Nature|April 16, 2025
An ultrasensitive method for detection of cell-free RNAMonica C Nesselbush, Bogdan A Luca, Young-Jun Jeon, et al.The Lancet. Digital Health|June 2, 2023
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective studyMaliazurina B Saad, Lingzhi Hong, Muhammad Aminu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2024
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort StudyAmin H Nassar, So Yeon Kim, Jacqueline V Aredo, et al.Nature|April 10, 2020
Integrating genomic features for non-invasive early lung cancer detectionJacob J Chabon, Emily G Hamilton, David M Kurtz, et al.Journal for Immunotherapy of Cancer|February 4, 2025
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registryAlessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio, et al.Journal for Immunotherapy of Cancer|September 29, 2025
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registryAlessio Cortellini, Valentina Santo, Leonardo Brunetti, et al.Pageof 52